Rexulti (brexpiprazole) is available in several dosage strengths to treat conditions such as schizophrenia and major depressive disorder [1].
What are the available Rexulti dosages?
Rexulti is manufactured in tablet form with the following dosage strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg [1].
How is Rexulti dosed for schizophrenia?
For schizophrenia in adults, the recommended starting dose of Rexulti is 1 mg orally once daily. After one week, the dosage may be increased to 2 mg orally once daily. The target dosage is typically 4 mg orally once daily, and the dose can be adjusted by increasing it by 1 mg increments at weekly intervals, up to a maximum of 4 mg once daily [1].
How is Rexulti dosed for major depressive disorder (MDD)?
When used as an adjunctive treatment for MDD in adults, the recommended starting dose of Rexulti is 0.5 mg or 1 mg orally once daily. After two weeks, the dosage may be increased to 2 mg orally once daily. The target dosage is typically 2 mg orally once daily, and the dose can be adjusted by increasing it by 1 mg increments at weekly intervals, up to a maximum of 3 mg once daily [1].
Are there dosage adjustments for specific patient groups?
Dosage adjustments for Rexulti may be necessary for patients who are also taking certain CYP1A2 inhibitors or CYP3A4/2D6 inhibitors [1].
When does Rexulti patent exclusivity end?
Information on patent expiry dates for Rexulti can be found on DrugPatentWatch.com [2]. Generally, patent expiry dates determine when generic versions of a drug can be introduced to the market.